Beyond digital content and branding, weve also worked on creating print materials, brochures, and point-of-sale displays for Sequoia, ensuring their presence is strong across all mediums
not FDA-approved as of June 2026
A 2018 paper in Current Pharmaceutical Design (Seiwerth S et al.) reviewed BPC-157's observed effects on angiogenesis - the formation of new blood vessels - and its potential role in tissue healing processes
Retatrutides type 2 diabetes trial documented meaningful glycemic (HbA1c) improvement alongside weight loss, [4] and its glucagon-driven biology has made hepatic fat (MASLD) a natural research question for the compound
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
A Bruker SamplePro liquid handler was used to prepare 10 samples: 8 samples containing an increasing ligand concentration from 50 to 500 M whilst maintaining a constant TRF1 TRFH concentration (2 M final)
